Vertex Pharmaceuticals Inc Form 4 Filings

VERTEX PHARMACEUTICALS INC / MA (symbol: VRTX) is the issuer of record for a Form 4 filing submitted to the SEC.

VERTEX PHARMACEUTICALS INC / MA (VRTX) director Bruce I. Sachs reported a disposition of common stock through a bona fide gift. On 2026-08-27, he transferred 6,000 shares of Vertex common stock, recorded at $0.00 per share for reporting purposes, and reported holding 39,000 shares directly afterward.

Vertex Pharmaceuticals reported a compensation-related equity grant to EVP and Chief Regulatory & Quality Officer Ourania Tatsis. She acquired 8,251 shares of common stock in the form of a restricted stock unit award on 07/21/2026, vesting on 03/31/2030, bringing her direct holdings to 53,572 shares.

Vertex Pharmaceuticals executive Amit Sachdev reported an acquisition of 8,251 shares of common stock on 2026-07-21 through a restricted stock unit award that vests on 03/31/2030. Following this award, he holds 66,512 shares directly, plus 882 shares indirectly via a 401(k) and 6,637 shares held in trust.

SACHS BRUCE I reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Bruce I. Sachs received a grant of 99.941 deferred stock units on July 15, 2026 at $475.28 per unit. Each unit represents one share of common stock, payable upon his board service ending, a change of control, disability, or death, bringing his directly held deferred stock units to 15,771.807.

Garber Alan M reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Alan M. Garber received a grant of 31.56 deferred stock units on July 15, 2026. Each unit represents one share of common stock and will be paid in shares upon the earliest of his board service termination, a change of control, or his disability or death. Following this award, he directly holds 65.458 deferred stock units tied to Vertex common stock.

Vertex Pharmaceuticals executive Ourania Tatsis reported an open-market sale of 1,500 shares of Common Stock. The transaction took place on July 2, 2026 at a price of $524.99 per share. The filing states that the sale was made pursuant to a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025, indicating it was pre-scheduled. After this transaction, Dr. Tatsis directly holds 45,321 shares of Vertex Pharmaceuticals common stock.

Vertex Pharmaceuticals executive Duncan McKechnie, EVP and Chief Commercial Officer, sold 1,541 shares of Common Stock in an open-market transaction at $519.00 per share on July 2, 2026. Following this sale, he directly holds 11,001 shares. The transaction was made under a company-approved trading plan pursuant to Rule 10b5-1 entered into on November 25, 2025, indicating it was pre-scheduled rather than discretionary.

Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock. On July 1, 2026, she sold 828 shares of Vertex common stock at an average price of $502.71 per share.

After this transaction, Liu directly holds 19,131 Vertex shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 25, 2025, indicating the trades were scheduled in advance rather than timed at her discretion.

Vertex Pharmaceuticals executive Dr. Carmen Bozic, EVP and CMO, sold 596 shares of Common Stock in an open-market transaction. The sale took place on June 26, 2026 at a price of $482.50 per share, for total proceeds of about $287,570.

The transaction was made under a company-approved Rule 10b5-1 trading plan that Dr. Bozic entered into on November 20, 2025, indicating it was pre‑scheduled rather than opportunistic. Following the sale, she directly owns 15,337 shares of Vertex common stock.

Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. As EVP and Chief Medical Officer, Bozic sold 1,020 shares of Vertex Pharmaceuticals common stock at a price of $462.17 per share on June 18, 2026.

After this transaction, Bozic directly holds 15,933 shares of Vertex common stock. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan, which was entered into on November 20, 2025, indicating the trade was pre-scheduled rather than timed discretionarily.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported an open-market sale of common stock. On June 15, 2026, she sold 4,062 shares of Vertex common stock at $450.00 per share. After this transaction, she directly holds 16,953 shares.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan approved by the company and entered into on November 20, 2025. This indicates the timing of the sale was set in advance as part of a structured trading program.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold 1,745 shares of common stock in an open-market transaction at $450 per share. The sale on June 5, 2026 was made under a company-approved Rule 10b5-1 trading plan. After the sale, she directly holds 21,015 shares.

Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock. As EVP and Chief Legal Officer, she sold 828 shares of Common Stock at a price of $439.91 per share on June 1, 2026. After this transaction, she directly holds 19,959 shares of Vertex common stock. The sale was made under a pre-arranged company-approved trading plan established pursuant to Rule 10b5-1, indicating it was scheduled in advance rather than timed discretionarily.

Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of 1,974 shares of Common Stock at $450.00 per share. The transaction left her with 22,760 shares held directly. According to the disclosure, the sale was made under a pre-arranged Rule 10b5-1 trading plan entered into on 11/20/2025, indicating it was scheduled in advance rather than timed discretionarily.

Vertex Pharmaceuticals executive Mark E. Bunnage reported a small open-market sale of company stock. On this Form 4, the EVP and Chief Scientific Officer sold 33 shares of Common Stock at $453.45 per share and now directly holds 7,284 shares. The transaction was made under a pre-arranged Rule 10b5-1 trading plan entered into on November 26, 2025.

Vertex Pharmaceuticals EVP and CMO Dr. Carmen Bozic sold 1,354 shares of Common Stock in an open-market transaction on May 15, 2026 at an average price of $453.45 per share. After this sale, she directly holds 24,734 shares. The trade was made under a pre-arranged Rule 10b5-1 company-approved trading plan entered into on November 20, 2025.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported an open-market sale of 6,988 shares of Common Stock at $450.00 per share. After this transaction, she directly holds 26,088 shares. The sale was carried out under a company-approved Rule 10b5-1 trading plan entered into on 11/20/2025.

Vertex Pharmaceuticals director Suketu Upadhyay reported routine equity compensation and a related share deferral. Upon vesting of previously granted restricted stock units, he exchanged 796 shares of common stock for 796 deferred stock units under the company’s deferred compensation plan, recording a disposition to the issuer and a matching derivative acquisition.

He also received a grant of 2,866 stock options exercisable at $424.45 per share, expiring on April 30, 2036. Following these transactions, he holds 1,558 shares of common stock, 3,595.156 deferred stock units, and 2,866 stock options, all reported as direct ownership.

Vertex Pharmaceuticals director Nancy Thornberry reported routine equity compensation changes. On May 1, 2026, she disposed of 398 shares of common stock back to the issuer in exchange for 398 deferred stock units under a deferred compensation plan, leaving 2,109 common shares at that step.

She then acquired 472 additional common shares as a grant, increasing her direct common stock holdings to 2,507 shares. Thornberry also received 398 deferred stock units, each linked to one share of common stock and payable upon specified future events, and a fully vested stock option for 1,433 shares with a $424.45 exercise price expiring on April 30, 2036.

Vertex Pharmaceuticals director Jennifer Schneider reported routine equity compensation changes. She disposed of 796 shares of common stock back to the company in exchange for 796 deferred stock units under a deferred compensation plan, so this was a non‑market, non‑cash swap rather than a sale.

Schneider also acquired 472 shares of common stock as a grant or award and received 796 deferred stock units, each representing one share of common stock payable upon certain future events. In addition, she was granted stock options for 1,433 shares at an exercise price of $424.45 per share, expiring in 2036, and now directly holds 1,394 shares of Vertex common stock.

Vertex Pharmaceuticals director Bruce I. Sachs reported an acquisition of stock options as compensation. He received a grant of 2,866 stock options for Vertex common stock at an exercise price of $424.45 per share. The options are fully vested and expire on April 30, 2036, and his direct derivative holdings after this grant total 2,866 options.

Vertex Pharmaceuticals director Diana McKenzie reported routine equity compensation and a deferral election involving company stock. She received a grant of 943 shares of common stock at no cost as a restricted stock unit award that will vest based on the grant terms.

Upon vesting of earlier restricted stock units granted on May 1, 2025, she chose to defer 796 shares of common stock into 796 deferred stock units under Vertex’s deferred compensation plan. This is recorded as a disposition of 796 common shares back to the issuer in exchange for an equal number of deferred stock units.

Each deferred stock unit represents one share of common stock and will be paid in stock upon the earliest of her board service ending, a change of control, or her disability or death. After these transactions, she holds 2,378 shares of common stock directly, 7,787.483 deferred stock units, and 207 common shares held indirectly in a trust.

Vertex Pharmaceuticals executive Joy Liu, EVP and Chief Legal Officer, sold 1,104 shares of Vertex common stock in an open-market transaction at $425.02 per share. The sale was made pursuant to a company-approved trading plan under Rule 10b5-1. After this transaction, Liu directly holds 20,729 shares of Vertex common stock.

Vertex Pharmaceuticals director Michel Lagarde received a fully vested stock option grant as part of his compensation. On May 1, 2026, he was awarded options to acquire 2,866 shares of Vertex common stock at an exercise price of $424.45 per share. These options are already fully vested and expire on April 30, 2036, and represent a routine, non‑market transaction rather than an open‑market trade.

Vertex Pharmaceuticals director Alan M. Garber received equity awards as compensation. He was granted 472 shares of Common Stock in the form of restricted stock units that vest, subject to limited exceptions, on the first anniversary of the grant date. He was also granted stock options for 1,433 shares of Common Stock at an exercise price of $424.45 per share, which are fully vested and expire on April 30, 2036. Following the stock grant, he directly holds 7,344 shares of Vertex Common Stock in addition to these options.

Vertex Pharmaceuticals director Lloyd Carney received a fully vested stock option grant covering 2,866 shares of common stock. The option has an exercise price of $424.45 per share and expires on April 30, 2036. Following this award, Carney holds 2,866 stock options directly.

Vertex Pharmaceuticals director Dr. Sangeeta N. Bhatia reported two common stock transactions. She received a grant of 943 shares as a restricted stock unit award that will vest, subject to limited exceptions, on the first anniversary of the grant date. She also completed an open-market sale of 318 shares at $423.73 per share under a company-approved trading plan pursuant to Rule 10b5-1, which was entered into on 05/27/2025. After these transactions, she directly holds 4,924 shares of Vertex common stock.

Upadhyay Suketu reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Suketu Upadhyay received a grant of 80.508 deferred stock units on common stock, recorded at a reference price of $442.50 per unit. Following this award, he holds a total of 2,799.156 deferred stock units.

Each deferred stock unit represents one share of common stock and will be paid in stock upon the earliest of his termination from the board, a company change of control, or his disability or death. This is a compensation-related award rather than an open-market trade.

SACHS BRUCE I reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Bruce I. Sachs received a routine equity grant in the form of deferred stock units. He was awarded 107.345 deferred stock units at a reference price of $442.50 per unit, each representing one share of common stock. After this grant, Sachs holds 15,671.866 deferred stock units. According to the terms, these units are paid out in common stock upon the earliest of his board service ending, a change of control of the company, or his disability or death.

Garber Alan M reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Alan M. Garber received a grant of 33.898 deferred stock units, each tied to one share of common stock. The units were valued at $442.50 per share and are payable in common stock upon the earliest of his board service ending, a change of control, or his disability or death. This represents routine equity-based board compensation rather than an open-market stock purchase or sale.

Vertex Pharmaceuticals executive Joy Liu, EVP and Chief Legal Officer, sold 978 shares of Common Stock in an open-market transaction on April 1, 2026, at an average price of $449.17 per share. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 25, 2025.

Following this planned sale, Liu directly holds 21,833 Vertex shares. The filing characterizes this as a routine insider transaction executed pursuant to a pre-arranged trading plan rather than a discretionary trade based on short-term market views.

Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 27, 2026, she sold 2,329 shares of Common Stock at an average price of $450.95 per share. After this transaction, she directly holds 33,076 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan that Dr. Bozic entered into on November 20, 2025, indicating the timing was set in advance.

Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 13, 2026, Dr. Bozic sold 2,329 shares of Vertex common stock at a price of $481.79 per share, as part of routine portfolio activity.

After this transaction, Dr. Bozic directly held 35,405 shares of Vertex common stock, indicating she retains a substantial ownership stake. The sale was carried out under a pre-established Rule 10b5-1 trading plan, meaning it was scheduled in advance under company-approved guidelines rather than timed opportunistically.

Vertex Pharmaceuticals executive Duncan McKechnie sold 2,633 shares of common stock in an open-market transaction. The sale occurred on March 11, 2026, at an average price of $498.42 per share. After the sale, he directly held 12,489 Vertex shares.

The transaction was made under a company-approved Rule 10b5-1 trading plan that Mr. McKechnie entered into on November 25, 2025, indicating the sale was pre-scheduled rather than opportunistic.

Vertex Pharmaceuticals executive reports planned share sale

Vertex Pharmaceuticals EVP and Chief Commercial Officer Duncan McKechnie sold 2,437 shares of common stock in an open-market transaction at $475.30 per share. After this sale, he directly holds 15,122 shares. The trade was made under a company-approved Rule 10b5-1 trading plan entered into on 11/25/2025.

Vertex Pharmaceuticals executive Joy Liu sold shares under a pre‑planned program. On March 2, 2026, she completed an open-market sale of 892 shares of Vertex common stock at $495.96 per share. After this transaction, she directly held 22,811 Vertex shares. The sale was made under a company-approved Rule 10b5‑1 trading plan entered into on November 25, 2025.

Vertex Pharmaceuticals CEO & President Reshma Kewalramani reported open-market sales of 40,000 shares of Vertex common stock on February 27, 2026 under a pre-arranged Rule 10b5-1 trading plan entered into on November 17, 2025. The shares were sold at prices ranging from $479.75 to $496.95, and she held 98,278 shares directly after the final transaction.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold common stock in a planned transaction. On February 27, 2026, she completed an open-market sale of 2,329 shares of Vertex common stock at an average price of $480.31 per share. After the sale, she directly owned 37,734 shares. The trade was made under a pre-established Rule 10b5-1 trading plan entered on November 20, 2025.

Vertex Pharmaceuticals senior vice president and chief accounting officer Kristen Ambrose reported an open-market sale of 357 shares of common stock at $483.36 per share. After this transaction, she directly holds 6,624 shares. The sale was made under a pre-established, company-approved Rule 10b5-1 trading plan.

Vertex Pharmaceuticals executive Charles F. Wagner Jr., the company’s EVP, COO and CFO, reported a Form 4 transaction involving company common stock. On February 24, 2026, he had 1,744 shares of Vertex common stock disposed of in a transaction coded “F,” which represents payment of tax liability by delivering securities, at a price of $485.11 per share. After this tax-withholding disposition, Wagner directly owned 47,042 shares of Vertex common stock.

Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported two transactions in Vertex common stock. She completed an open-market sale of 260 shares at $486.35 per share under a company-approved Rule 10b5-1 trading plan. In a separate transaction, she disposed of 1,627 shares at $485.11 per share to cover tax obligations. After these transactions, she directly holds 46,763 shares of Vertex common stock.

Vertex Pharmaceuticals executive Amit Sachdev reported share sales and related tax withholding transactions. On February 25, 2026, he completed an open-market sale of 1,846 shares of common stock at $486.35 per share, leaving him with 55,570 directly held shares.

On February 24, 2026, he disposed of 1,518 shares of common stock at $485.11 per share to cover tax obligations by delivering shares. He also reported indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in a trust. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 18, 2025.

Vertex Pharmaceuticals executive Duncan McKechnie reported multiple stock transactions. On February 25, 2026, he made open-market sales of 2,500 common shares at $486.35 per share and 2,410 shares at $489.00 per share.

On February 24, 2026, 873 shares were disposed of at $485.11 per share to cover tax obligations by delivering shares. After these transactions, he directly owned 17,559 Vertex common shares. The filing notes the sales were made under a company-approved Rule 10b5-1 trading plan entered on November 25, 2025.

Vertex Pharmaceuticals Executive Chairman Jeffrey M. Leiden reported a Form 4 transaction involving a tax-withholding disposition of 3,547 shares of common stock at $485.11 per share on February 24, 2026. After this transaction, he directly owned 34,797 shares and indirectly held 440 shares through a 401(k) plan.

Vertex Pharmaceuticals CEO Reshma Kewalramani reported a tax-related share transaction. On this Form 4, she had 4,981 shares of common stock withheld at $485.11 per share to cover taxes, a type of non-market disposition. After this, she directly owned 138,278 shares of Vertex common stock.

Vertex Pharmaceuticals executive Mark E. Bunnage reported two stock dispositions. On February 25, 2026, he completed an open-market sale of 620 shares of common stock at an average price of $486.35 per share. After this sale, he directly held 7,284 shares.

On February 24, 2026, he disposed of 582 shares at an average price of $485.11 per share to cover tax obligations, rather than as an open-market sale. The transactions were made under a company-approved Rule 10b5-1 trading plan that Dr. Bunnage entered into on November 26, 2025.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported a tax-related share disposition. On February 24, 2026, she transferred 1,453 shares of Vertex common stock at an indicated price of $485.11 per share to cover tax obligations by delivering shares rather than cash. After this tax-withholding transaction, she directly owned 40,063 Vertex common shares.

Vertex Pharmaceuticals EVP and Chief Legal Officer Jonathan Biller sold 945 shares of common stock on February 25, 2026 at $486.35 per share in an open-market trade under a Rule 10b5-1 plan entered on February 24, 2025. On February 24, 2026, 1,144 shares were also disposed of to cover tax withholding, leaving 13,659 directly owned shares.